High Freedom from Clinically-Driven TLR through 3 Years

Significant Improvement in Walking Capacity as Measured by WIQ

Stent Sizes and Specifications

Data on file at Abbott unless otherwise noted.

^-1.81% shortening for 8.0 mm x 38 mm size.
*Combined clinical results from BRAVISSIMO study where 66%/34% of TASC C lesions were treated with Absolute Pro™ Vascular Self-Expanding Stent System / Omnilink Elite™ Vascular Balloon-Expandable Stent System respectively.
**Combined clinical results from BRAVISSIMO study where 54%/46% of TASC D lesions were treated with Absolute Pro™ Vascular Self-Expanding Stent System / Omnilink Elite™ Vascular Balloon-Expandable Stent System respectively.
^^Compatible with sheath inner diameters of 2.15 and 2.20 mm for 9 mm x 39 mm, 59 mm and 10 mm x 19 mm, 29 mm, 39 mm stents, respectively.
^†Omnilink Elite™ PERIPHERAL Vascular Balloon-Expandable Stent System Instructions For Use (IFU). Refer to IFU for additional information.

References

1. Pache, et al. Intracoronary stenting and angiographic results: strut thickness effect on restenosis outcome (ISAR-STEREO-2) trial. JACC 2003; 41:1283-8.
2. Donato, G. et al. 24-Month Data from the BRAVISSIMO: A Large-Scale Prospective Registry on Iliac Stenting for TASC A & B and TASC C & D Lesions. Annals of Vascular Surgery. 2015; 29(4): 738-750.